ABSTRACT
The Good Clinical Practice (GCP) regulations outline the respective responsibilities of the clinical investigator, the drug sponsor, and the clinical study monitor involved in investigational new product development. This entry discusses the qualifications of GCP by addressing each stage of the clinical process individually in terms of obligations, for example, the obligations of the sponsor in the study and also those of the investigator, and how they work together in complying with GCP.
